Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related death in the United States. 1 Over the past decade, numerous studies have indicated that combining 5-fluorouracil (5-FU)/leucovorin (LV) with irinotecan and/or oxaliplatin can prolong survival in patients with advanced CRC. A common toxicity of these combination regimens is neutropenia. 2,3 Neutropenia increases the risk for infection presenting as febrile neutropenia (FN), which can lead to chemotherapy dose reductions and delays, hospitalizations, and death. 4, 5 The rate of grade 3/4 neutropenia in patients with advanced CRC has been reported to be 42% in patients receiving an every-2-week regimen of FOLFOX (5-FU/ LV/oxaliplatin), 2 46% in patients receiving a every-2-week regimen of FOLFIRI (5-FU/LV/irinotecan), 3 and over 50% in patients receiving an every-2-week regimen of FOIL (5-FU/LV/oxaliplatin/irinotecan irinotecan] at physician discretion). The primary endpoint was incidence of grade 3/4 neutropenia. Secondary endpoints included incidence of grade 3/4 FN and adverse events. After 4 cycles of study treatment, progression-free survival (PFS) and overall survival (OS) were followed for ≤ 2 years in long-term follow-up. Results: Of 241 eligible patients analyzed, 118 were in the placebo and 123 in the pegfilgrastim group. In the treatment period, the odds ratio for grade 3/4 neutropenia for pegfilgrastim versus placebo was 0.19 (95% CI, 0.10-0.37; P < .001); grade 3/4 FN incidence was also significantly lower in pegfilgrastim-treated patients (2%) compared with placebo-treated patients (8%; P = .04). Pegfilgrastim was well tolerated, with leukocyte counts remaining stable during cycles 2-4. In long-term follow-up, both treatment groups had similar PFS and OS. Conclusion: Pegfilgrastim was well tolerated in patients with CRC receiving every-2-week chemotherapy and significantly reduced neutropenia and FN compared with placebo, though FN was uncommon in both treatment groups. Results suggest that pegfilgrastim administration is feasible in CRC patients receiving every-2-week chemotherapy.
Pegfilgrastim, a granulocyte colony-stimulating factor (G-CSF), is approved in the United States to decrease the risk of infections in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of FN. 7 The pegfilgrastim labeling information recommends that pegfilgrastim not be administered in the period between 14 days before and 24 hours after chemotherapy administration. 7 For every-2-week regimens incorporating infusional 5-FU, an 11-day interval would exist between administration of pegfilgrastim and the next cycle of chemotherapy. To date, limited data exist regarding this schedule of pegfilgrastim administration. Previous pharmacokinetic data have shown, however, that pegfilgrastim levels generally reach subtherapeutic levels (with recovery of absolute neutrophil counts) by day 12 after administration, suggesting that pegfilgrastim administration with every-2-week chemotherapy was possible. 8, 9 This randomized, placebo-controlled phase II study was designed to evaluate whether prophylactic pegfilgrastim administered with first-or second-line chemotherapy was feasible and reduced the incidence of grade 3/4 neutropenia and neutropenia-related complications in patients receiving 14-day oxaliplatin-or irinotecan-containing 5-FU-based chemotherapy regimens for advanced or metastatic CRC.
Patients and Methods

Patients
Eligible patients (≥ 18 years of age) had locally advanced or metastatic colorectal adenocarcinoma not curable by surgery and not amenable to curative radiation therapy; life expectancy of ≥ 12 weeks; Eastern Cooperative Oncology Group performance status of 0-2; and adequate hematopoietic, liver, and kidney functions. Patients could have received adjuvant chemotherapy and up to 1 previous chemotherapy regimen for metastatic disease, provided that 30 days had elapsed since the last dose of chemotherapy received.
Exclusion criteria included previous exposure to both oxaliplatin and irinotecan, previous radiation therapy to > 15% of bone marrow, standard adjuvant rectal cancer chemoradiation, active infection requiring systemic anti-infective therapy within 72 hours of the first administration of study chemotherapy, sensory peripheral neuropathy, uncontrolled bowel disorders, sensitivity to Escherichia coli-derived products, and previous malignancy (except for adequately treated basal cell carcinoma or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancer for which the patient has been disease free for at least 5 years).
Study Design
This was a 1:1 randomized, double-blind, placebo-controlled study with patients receiving pegfilgrastim 6 mg in the experimental arm. Randomization was stratified by chemotherapy regimen. Patients received one of three every-2-week chemotherapy regimens at physician discretion. The allowed regimens included:
(1) FOLFOX4: oxaliplatin 85 mg/m 2 on day 1, LV 200 mg/m 2 intravenously (I.V.) on days 1 and 2, 5-FU 400 mg/m 2 bolus then 600 mg/m 2 administered over 22 hours on both days 1 and 2.
(2) FOLFIRI: irinotecan 180 mg/m 2 on day 1, LV 200 mg/m 2 I.V. on days 1 and 2, 5-FU 400 mg/m 2 bolus then 600 mg/m 2 administered over 22 hours on both days 1 and 2. A patient who previously received oxaliplatin could receive only the FOLFIRI regimen. A patient who previously received irinotecan could receive only the FOLFOX4 regimen. Patients received a single subcutaneous injection of either pegfilgrastim or placebo approximately 24 hours after completion of the 5-FU infusion for 4 chemotherapy cycles (study treatment period). Patients had the option to continue to receive chemotherapy and investigational product for an additional 8 cycles (maximum, 12 cycles). Chemotherapy treatment was repeated every 2 weeks until disease progression, physician decision, chemotherapy delay of > 3 weeks, or withdrawal of consent.
Full-dose chemotherapy was administered on day 15 (day 1 of the next cycle) if the absolute neutrophil count (ANC) was ≥ 1.5 × 10 9 /L and platelet count was ≥ 100 × 10 9 /L; study chemotherapy was delayed until adequate counts were documented. Chemotherapy could be reduced by 25% in each cycle if deemed necessary by the investigator. Patients who experienced FN had a 25% reduction of all the chemotherapy agents in subsequent cycles. Once chemotherapy doses were reduced, escalation was not allowed.
Patients could receive any US Food and Drug Administration-approved targeted-therapy monoclonal antibodies and any concomitant medications needed for adequate supportive care, excluding investigational agents, white blood cell (WBC) transfusions, hematopoietic growth factors (erythropoiesis-stimulating agents were allowed), and corticosteroids (topical steroids or premedications for study chemotherapy or treatment of an adverse event were allowed).
Study Endpoints and Assessments
The primary endpoint was the incidence of grade 3/4 neutropenia (ANC < 1.0 × 10 9 /L) during the first 4 cycles of chemotherapy (study treatment period). Secondary endpoints included incidence of grade 3/4 FN (temperature ≥ 38.2°C and an ANC < 1.0 × 10 9 /L on the same day or the day after), neutropenia-related hospitalization rate and related antibiotic use, incidence of chemotherapy dose delays and/or dose reductions because of a neutropenic event, objective response rates, and incidence of adverse events.
Febrile neutropenia was determined from reported temperatures and from observed ANCs and was not based on adverse event reports. At the start of each chemotherapy cycle, blood was drawn for a complete blood count (CBC; with 5-part differential) and the patient's temperature was taken by their healthcare provider. Between cycles, patients were advised to closely monitor their temperatures and to contact their doctor or local emergency room in the case of a fever (temperature ≥ 38.2°C) to arrange for a CBC (with 5-part differential).
During long-term follow-up, time to progression and overall survival (OS) were examined at 6, 12, 18, and 24 months after the study treatment period ended (after 4 chemotherapy cycles). If a patient ended treatment before completing 4 cycles of chemotherapy, survival information was collected at 6, 12, and 24 months after study treatment ended. Administration of study drug was optional during the follow-up period.
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Statistical Methods
Efficacy and safety analyses were performed only after all randomized patients had the opportunity to complete at least 4 cycles of chemotherapy. Analyses were performed on randomized, consented patients who received at least 1 dose of study drug. Patients were analyzed according to randomization assignment in the efficacy analysis set and according to treatment received in the safety analysis set.
Sample size was based on the assumption that the rate of grade 3/4 neutropenia without growth factor support would be approximately 40% and that the addition of pegfilgrastim would reduce this rate by at least 40%. Enrolling 300 patients (150 per treatment arm) would provide 80% power with a Type I error probability of 0.05 to detect a 40% relative reduction in incidence of grade 3/4 neutropenia between patients who did or did not receive pegfilgrastim.
All statistical tests were performed at the α = 0.05 level, 2-sided, with no adjustments for multiplicity. For efficacy endpoints, incidence rates were estimated for each treatment arm with 2-sided 95% confidence intervals (CIs). Incidences for efficacy endpoints were compared between arms using a Cochran-Mantel-Haenszel strata-adjusted χ 2 test and logistic regression analysis. For each chemotherapy stratum, the incidences were compared between arms using the Fisher exact test. Time to progression and OS were estimated in each treatment group from cycle 1 day 1 using the Kaplan-Meier method. The study was not powered to detect differences between the placebo and pegfilgrastim groups in terms of progression-free survival (PFS) and OS.
Results
This randomized, placebo-controlled phase II study was conducted at 54 sites in the United States between February 2003 and March 2008. The study protocol was reviewed and approved by the institutional review board at each study site, and written informed consent was obtained from each patient before enrollment.
Patients
Enrollment was closed before the planned 300 patients were obtained because of slow recruitment. Of 316 patients screened, 252 were enrolled (126 patients in each arm; Figure 1 ). No changes to the statistical analysis were implemented based on lower-thanplanned enrollment. The primary analysis set consisted of 241 randomized, consented patients who received at least 1 dose of study drug (118 placebo; 123 pegfilgrastim). Approximately half the patients received FOLFOX4, whereas FOLFIRI and FOIL were each received by about a quarter of the patients.
Across both treatment groups, 188 patients (78%) completed 4 cycles of treatment. Rates of treatment completion, patient attrition, and reasons for early discontinuation did not differ appreciably between the pegfilgrastim and placebo treatment groups (Figure 1) . Of the 241 patients in the primary analysis set, 191 (90 placebo; 101 pegfilgrastim) entered the follow-up period, 67 (24 placebo; 43 pegfilgrastim) received up to 8 cycles of additional study drug (per study protocol) during follow-up, and 170 (81 placebo; 89 pegfilgrastim) completed the follow-up period.
Patient demographics for those in the primary analysis set are shown in Table 1 . There were no appreciable differences in baseline disease characteristics between the two treatment groups overall or within each chemotherapy regimen stratum. Figure 1 a Patients who did not complete all 4 cycles in the treatment period could enter the follow-up period. b A patient was considered to have completed the follow-up period if the patient had data for the 24 month visit or died during the follow-up period. 
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Primary Endpoint
The primary endpoint was the incidence of grade 3/4 neutropenia (defined as ANC < 1.0 × 10 9 /L) during the first 4 cycles of treatment. Overall, patients treated with pegfilgrastim were significantly less likely to experience grade 3/4 neutropenia than were those receiving placebo ( Table 2 ). The reduction was observed in each of the regimens.
Febrile Neutropenia and Hospitalizations Due to a Neutropenic Event
Over the first 4 cycles, pegfilgrastim use resulted in a 75% reduction in grade 3/4 FN (8% in the placebo group and 2% in the pegfilgrastim group; odds ratio [OR], 0.27; 95% CI, 0.07-1.00; P = .04). This reduction was also observed in all 3 chemotherapy regimens separately. The incidence of patients who were hospitalized for neutropenic events was 8% in the placebo group and 6% in the pegfilgrastim group (P = .55). Antibiotic use due to FN was 7% in the placebo group and 2% in the pegfilgrastim group (OR, 0.23; 95% CI, 0.05-1.09; P = .046). Similar reductions were observed considering each of the chemotherapy regimens separately.
Dose Delays or Dose Reductions
The incidence of dose delays for any reason during the first 4 cycles for all regimens combined was higher (P = .003) in the placebo group compared with the pegfilgrastim group ( Table 3 ). The incidence of dose reductions for any reason was similar in both treatment groups. The incidence of dose delays or reductions for any reason was numerically higher in the placebo group than in the pegfilgrastim group (P = .06).
Across the first 4 cycles of chemotherapy for all regimens combined, the proportion of patients with a neutropenia-related dose delay, dose reduction, and either dose delay or reduction was significantly higher in the placebo group than in the pegfilgrastim group (P values ranged from < 0.001 to 0.02; 84 (71) 16 (14) 12 (10) 6 ( 67 (57) 11 (9) 0 (0) 58 (49) 30 (25) 30 ( 103 (84) 3 (2) 12 (10) 5 (4) 1 (0.8)
112 (95) 4 (3) 58 (47) 52 (42) 11 (9) 2 (2) 61 (50) 32 (26) 30 ( 
Objective Response Rate
During the treatment period, the incidence of patients with a complete or partial response was similar in the placebo (31%) and pegfilgrastim (28%) groups. The incidence of stable disease was 31% in the placebo group and 41% in the pegfilgrastim group. For the individual chemotherapy regimens, there were no significant differences between the placebo and pegfilgrastim groups in achievement of either partial or complete response.
Progression-Free Survival and Overall Survival in LongTerm Follow-up
Of the 241 patients in the primary analysis set, 191 (90 placebo; 101 pegfilgrastim) entered the follow-up period of the study. The median follow-up time combining both treatment groups was 17.1 months (519 days). Using the Kaplan-Meier method, the percentages of patients with a PFS event were estimated to be 91% (placebo group) and 85% (pegfilgrastim group). The median PFS times were similar between the groups (Figure 2) .
Using the Kaplan-Meier method, the estimated percentages of patients who died were 58% (placebo group) and 46% (pegfilgrastim group). At the last follow-up, 49 of 118 patients in the placebo group had died compared with 47 of 123 patients in the pegfilgrastim group. The median survival time for the placebo group was 25.6 months (95% CI, lower limit = 19.5, upper limit = could not be estimated), and the median survival time for the pegfilgrastim group could not be estimated because of lack of events (Figure 3 ).
Exposure to Study Drug
The percentage of patients who received 4 doses of study drug during the first 4 cycles of chemotherapy was similar in the placebo (74%) and pegfilgrastim (79%) groups. The percentage of patients who received additional colony-stimulating agents (mainly filgrastim) was 2% in the placebo group (3 of 124 patients) compared with 14% in the pegfilgrastim group (16 of 117 patients).
Safety
The incidence of all adverse events was similar between the placebo and pegfilgrastim groups according to the descriptive adverse event summaries (Table 4) . Other adverse events reported at low frequency in this study were deep vein thrombosis (5.1% placebo vs. 4% pegfilgrastim), sepsis (0.9% placebo vs. 1.6% pegfilgrastim), thrombocytopenia (7.7% placebo vs. 7.3% pegfilgrastim), neuropathy (4.3% placebo vs. 6.5% pegfilgrastim), peripheral neuropathy (2.6% placebo vs. 5.6% pegfilgrastim), and leukocytosis (2.6% placebo vs. 5.6% pegfilgrastim).
The incidence of bone pain was low across both treatment groups although higher in the pegfilgrastim group (10%) compared with the placebo group (1%). All reported bone pain adverse events were grade 1 or 2 except for 1 incident of grade 3 bone pain in the pegfilgrastim arm. Bone pain considered related to study drug occurred in 0 patients receiving placebo and in 10 patients (8%) receiving pegfilgrastim.
Seven patients (6%) in each group died during the treatment period. No event leading to death was considered related to study drug. Treatment-related adverse events were lower in the placebo group (12%) compared with the pegfilgrastim group (19%). Five pegfilgrastim-treated and no placebo-treated patients experienced leukocytosis that was related to study drug.
The incidence of serious adverse events was similar between the two groups (Table 4) . No serious adverse events were considered related to the study medication. White blood cell counts remained stable in the patients treated with pegfilgrastim from cycle 2 to cycle 4 of chemotherapy (Table 5) . 
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For those patients who received the 8 additional cycles of study drug during the follow-up period, the percentage of patients with serious adverse events was 13% (3 of 24) in the placebo group and 7% (3 of 43) in the pegfilgrastim group. The most common serious adverse events were gastrointestinal disorders (8% placebo; 2% pegfilgrastim). No serious adverse events related to the study drug administered were reported during the follow-up period.
Discussion
This study demonstrated that pegfilgrastim administered on day 4 of an every-2-week CRC chemotherapy regimen significantly reduced the incidence of grade 3/4 neutropenia (P < .001). Although the incidence of FN was relatively low with these regimens, pegfilgrastim-treated patients had significantly less grade 3/4 FN compared with placebo-treated patients (2% vs. 8%; OR, 0.27; 95% CI, 0.07-1.00; P = .04). Pegfilgrastim use also reduced chemotherapy dose delays and dose reductions due to neutropenia.
Overall, pegfilgrastim was well tolerated. An increased incidence of mostly mild-to-moderate bone pain was reported in the pegfilgrastim arm versus the placebo arm (10% vs. 1%). This incidence was lower than that recently reported in a study of patients with breast cancer receiving taxane-based chemotherapy in which bone Table 4 a Adverse events that occurred in ≥ 10% of patients in any treatment group are listed in descending order of frequency of occurrence in the pegfilgrastim group. b Patients in the safety analysis set were analyzed according to treatment received. White Blood Cell Counts Table 5 Abbreviations: max = maximum; min = minimum; WBC = white blood cell Blood Cell Count pain was experienced by 31% of pegfilgrastim-treated patients and 27% of placebo-treated patients, 10 suggesting that the incidence of bone pain might be affected by cancer diagnosis or treatment regimen. Thus, some reported bone pain might be regimen and/ or diagnosis related.
Placebo (n = 117)
In this study, there was an 11-day interval between the administration of pegfilgrastim and the next cycle of chemotherapy. However, WBC counts recorded at each cycle (baseline to end of treatment) indicated that ANC recovery before the next chemotherapy cycle occurred in the pegfilgrastim-treated arm without leukocytosis, cycle delays, or associated adverse sequelae.
There were no significant differences between treatment groups in PFS or OS in the long-term follow-up period, suggesting that the use of pegfilgrastim in this patient population did not impact long-term patient outcomes.
Even though the study was not powered for OS and PFS hypothesis testing, the OS and PFS results are consistent with results from previous studies in lymphoma 11 and breast cancer 12 that did not indicate increased risk of tumor progression or death with pegfilgrastim use.
Although the low incidence of FN in the placebo group suggests that FN complications might not frequently occur in this patient population, patients enrolled in clinical trials often are healthier than patients treated in the general medical community. [13] [14] [15] Furthermore, though most treatment for metastatic CRC is palliative and might not require maintaining intensity of chemotherapy dose (particularly when using chemotherapy agents with dose-limiting toxicities such as oxaliplatin-associated neuropathy), there has been the recent realization that some patients with inoperable metastatic disease might become resectable and potentially curable with neoadjuvant treatment. 16 These patients may benefit from maintaining chemotherapy dose intensity, which appears to be facilitated by pegfilgrastim use.
Conclusion
The results from this study support the feasibility of using pegfilgrastim with every-2-week chemotherapy regimens in patients with CRC and support the efficacy of pegfilgrastim in preventing neutropenia across regimens and tumor types. Further evaluation of pegfilgrastim may be warranted in patients with CRC who are at a high risk for complications or who are candidates for potentially curative surgery following chemotherapy administration.
